Search Constraints
« Previous |
1 - 20 of 29
|
Next »
Search Results
Select an image to start the slideshow
Evaluating the Association of Structural Racism with Acuity and Severity at Initial Presentation in Pediatric Patients with Solid Tumors
1 of 20
Association of Patient and Caregiver Distress with Referral to a Palliative Care Clinic in Pediatric Oncology
2 of 20
Exploring The Phenotypic Effects of Toll Signaling Pathways In Tumor Progression in EGFR-driven Glioblastoma Models
3 of 20
A 3D Co-culture Spheroid Screening System for Studying the Malignant Transformation of Ductal Carcinoma in situ to Invasive Ductal Carcinoma
4 of 20
Functional, genomic, and radiographic associations with outcomes in IDH-mutant glioma: experience from a high-volume tumor center
5 of 20
Immunologic Mechanisms of Colorectal Liver Metastases: Potential for Novel Therapies
6 of 20
Understanding and Optimizing Gamma-Delta T cells as a Platform for Cellular Immunotherapies
7 of 20
Modulating Mitofusins to Enhance Therapeutic T Cell Expansion and Persistence
8 of 20
Real World Outcomes of Melanoma Brain Metastases Treated with Immunotherapy with or without Stereotactic Radiosurgery
9 of 20
Galectin-9 Expression and its Role in Biliary Tract Cancers
10 of 20
The association of health status and health quality with physical activity in childhood cancer survivors
11 of 20
Elucidating the Role of Soluble Galectin-9 in B-cell Acute Lymphoblastic Leukemia Pathogenesis
12 of 20
The Role of Metabolic Enzymes in Immunotherapy Resistance in Non-Small Cell Lung Cancer
13 of 20
Evaluation of tumor membrane vesicle (TMV) vaccine immunotherapy in a HER2+ TUBO murine breast cancer model
14 of 20
Impact of Hepatitis C Treatment on Long-term Outcomes for Patients with Hepatocellular Carcinoma
15 of 20
Exploring Innate Immunity Pathways in the Sex-Based Differences of Glioblastoma using Drosophila melanogaster Models
16 of 20
Inhibiting VIP Receptor Signaling Promotes T Cell Mediated Immune Response in Murine Melanoma Models
17 of 20
A Data-Driven Approach to Define Parsimonious Eligibility Criteria in First-Line Clinical Trials for Diffuse Large B-Cell Lymphoma
18 of 20
Physical Activity’s Impact in Lymphoma Patient’s Outcomes
19 of 20
Determining the mechanism behind imipramine blue’s selectivity towards FLT3-ITD+ acute myeloid leukemia
20 of 20